Research finds ECOG scores restrict patient access to trials, preventing trials from accurately representing real-world patients

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).

Language barriers hinder diverse recruitment to clinical trials

Underrepresentation of racial and ethnic minority populations in cancer clinical trials persists partly because translation and interpretation services and resources are unavailable or inadequate in the United States, according to a Children’s Oncology Group study led by Columbia University School of Nursing.

August 02, 2024

Vol.50 No.31

Regulatory News

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.

July 26, 2024

Vol.50 No.30

By Jacquelyn Cobb and Paul Goldberg

In Brief

Newman, Salami named associate directors at UMich Rogel Cancer Center

Erika Newman was named associate director for cancer health equity, and Simpa Salami was named associate director for research workforce and leadership development at Rogel Cancer Center.

July 26, 2024

Vol.50 No.30

In Brief

Sarah Bigelow named executive director of Tulane Cancer Center Clinical Trials Office

Sarah Bigelow was named executive director of the Clinical Trials Office at the Tulane Cancer Center.

July 05, 2024

Vol.50 No.27

Clinical

NCI’s Virtual Clinical Trials Office fills the staffing shortages at cancer centers

Cancer centers that continue to experience pandemic-induced shortages in staffing their clinical research enterprise may soon be able to rely on support from NCI’s Virtual Clinical Trials Office to open studies and accrue patients.

June 28, 2024

Vol.50 No.26

By Matthew Bin Han Ong

Research finds ECOG scores restrict patient access to trials, preventing trials from accurately representing real-world patients

YOU MAY BE INTERESTED IN

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

Language barriers hinder diverse recruitment to clinical trials

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Newman, Salami named associate directors at UMich Rogel Cancer Center

Sarah Bigelow named executive director of Tulane Cancer Center Clinical Trials Office

NCI’s Virtual Clinical Trials Office fills the staffing shortages at cancer centers

Renew today!

Subscriber content

Login

Research finds ECOG scores restrict patient access to trials, preventing trials from accurately representing real-world patients

YOU MAY BE INTERESTED IN

Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC

Language barriers hinder diverse recruitment to clinical trials

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Newman, Salami named associate directors at UMich Rogel Cancer Center

Sarah Bigelow named executive director of Tulane Cancer Center Clinical Trials Office

NCI’s Virtual Clinical Trials Office fills the staffing shortages at cancer centers

Login

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC